-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FwjyMEoRp6OpW3z1cbtPP+TGTDsSAc6rs49PcoiXhUJjjdIYftdJc44eLXczG7LQ 8CRfmVi8gSl9PGK0rtTN4w== 0001104659-05-009147.txt : 20050302 0001104659-05-009147.hdr.sgml : 20050302 20050302163325 ACCESSION NUMBER: 0001104659-05-009147 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20050302 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20050302 DATE AS OF CHANGE: 20050302 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMYLIN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000881464 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330266089 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19700 FILM NUMBER: 05654706 BUSINESS ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6195522200 MAIL ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 a05-4412_18k.htm 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 2, 2005

 

AMYLIN PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

0-19700

33-0266089

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

 

9360 Towne Centre Drive, Suite 110
San Diego, California

92121

(Address of principal executive offices)

(Zip Code)

 

Registrant’s telephone number, including area code:  (858) 552-2200

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Item 1.01 Entry into a Material Definitive Agreement.

 

On March 2, 2005, Amylin Pharmaceuticals, Inc. and Baxter Pharmaceutical Solutions LLC entered into a Commercial Supply Agreement, pursuant to which Baxter will supply Amylin with SYMLIN® (pramlintide acetate) injection in vials. If Amylin receives approval from any regulatory authority, including the United States Food and Drug Administration, to market this product, then following the first calendar year of the date of any such approval Amylin will be required to make minimum annual purchases from Baxter. The Supply Agreement has a term of five years. Amylin and Baxter each have normal and customary termination rights, including termination for material breach or upon various financial events.  In addition, Amylin may terminate the Supply Agreement at any time if any regulatory authority denies or withdraws approval of this product, or if Baxter loses its manufacturing authorizations for SYMLIN.  Amylin and Baxter are also parties to a Commercial Supply Agreement dated February 14, 2005, in which Amylin engaged Baxter to manufacture exenatide drug product in cartridges for twice-daily injection.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

AMYLIN PHARMACEUTICALS, INC.

 

 

 

 

 

 

 

 

 

Dated: March 2, 2005

By:

/s/ LLOYD A. ROWLAND

 

 

 

Lloyd A. Rowland

 

 

 

Vice President, Legal, Secretary and General Counsel

 

 

 -----END PRIVACY-ENHANCED MESSAGE-----